Suven gets US patent office nod for neuro drug

Suven gets US patent office nod for neuro drug


Mumbai: Pharmaceutical firm Suven Life Sciences said on 27 December the US Patent office has granted product patent for compounds used in the treatment of neuro- degenerative disorders.

“We are very pleased by the issuance of this patent to Suven by US Patent office for our drug candidates that are being developed for CNS disorders which targets a 18-billion dollar potential market opportunity" Suven Life Sciences’ CEO Venkat Jasti said.

Suven has been granted product patent ‘US 7,297,711’, its first product patent in the United States, the company said in a filing to the Bombay Stock Exchange.

According to the invention ‘711’ patent disclosure, the compounds are useful in the treatment of neuro-degenerative disorders like Alzheimer’s Parkinson, Schizophrenia and Huntington’s.

Suven has so far filed 29 product patent applications through Patent Cooperation Treaty CT covering more than 145 countries, of which five patents have been granted in various countries.

Several other patent applications from Suven Discovery Research are in the pipeline, which have completed administrative and technical diligence from the patent offices from major countries, the company added.

Suven has filed its first Investigational New Drug (IND) application with DCGI to conduct the clinical Phase-I study on their developmental candidate SUVN-502 and several candidates are in discovery pipeline undergoing GLP pre-clinical studies.

Shares of Suven were trading at Rs50.80, up 9.01% on the BSE in morning trade.